Cargando…

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition

Hepatocellular carcinoma (HCC) constitutes most primary liver cancers and is one of the most lethal and life-threatening malignancies globally. Unfortunately, a substantial proportion of HCC patients are identified at an advanced stage that is unavailable for curative surgery. Thus, palliative thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Shengwei, Liang, Shuhang, Zeng, Taofei, Yin, Dalong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845774/ https://www.ncbi.nlm.nih.gov/pubmed/36685594 http://dx.doi.org/10.3389/fimmu.2022.1043667

Ejemplares similares

Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
por: Saleh, Reem, et al.
Publicado: (2020)

Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma
por: Wu, Zeng-Hong, et al.
Publicado: (2021)

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
por: Tong, Huan, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Commentary: Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints
por: Xu, Fangshi, et al.
Publicado: (2023)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
por: Engelsen, Agnete S. T., et al.
Publicado: (2022)

Interleukin-33: Metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells
por: Lin, Jian, et al.
Publicado: (2022)

Intracerebral opportunistic infections caused by immunosuppressants after orthotopic liver transplantation: Report of two cases and literature review
por: Guo, Yafei, et al.
Publicado: (2022)

Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Xu, Shuo, et al.
Publicado: (2021)

Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints
por: Wang, Xiaoqiang, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
por: Wang, Caie, et al.
Publicado: (2023)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas
por: Wang, Mona Meng, et al.
Publicado: (2023)

The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
por: Torres-Zurita, Alberto, et al.
Publicado: (2023)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Advances in epigenetic modifications of autophagic process in pulmonary hypertension
por: Mao, Min, et al.
Publicado: (2023)

Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
por: Liu, Kwei-Yan, et al.
Publicado: (2018)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
por: Ke, Qiao, et al.
Publicado: (2022)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma
por: Elsegood, Caryn L, et al.
Publicado: (2017)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications
por: Li, Yijia, et al.
Publicado: (2021)

Inflammation-Related Epigenetic Modification: The Bridge Between Immune and Metabolism in Type 2 Diabetes
por: Ding, Qiyou, et al.
Publicado: (2022)

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition
por: van Dorp, Jeroen, et al.
Publicado: (2023)

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
por: Sundar, Raghav, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5be77lguburkcfjislb3crhok1